# Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

> **NCT05922124** · PHASE4 · RECRUITING · sponsor: **Rambam Health Care Campus** · enrollment: 734 (estimated)

## Conditions studied

- Carbapenem Resistant Bacterial Infection
- Acinetobacter Bacteremia
- Acinetobacter Pneumonia

## Interventions

- **DRUG:** Cefiderocol
- **DRUG:** Ampicillin-sulbactam
- **DRUG:** Colistin
- **DRUG:** Meropenem

## Key facts

- **NCT ID:** NCT05922124
- **Lead sponsor:** Rambam Health Care Campus
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2026-07
- **Final completion:** 2026-09
- **Target enrollment:** 734 (ESTIMATED)
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05922124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05922124, "Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05922124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*